Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey

• Published in: Japanese journal of clinical oncology 2023-01, Vol.53 (2), p.146-152
• Main Authors: Kawamura, Hidemasa, Nakamura, Katsumasa, Yoshioka, Yasuo, Itasaka, Satoshi, Tomita, Natsuo, Onishi, Masahiro, Iwata, Hiromitsu, Aizawa, Takuya, Kikuchi, Koyo, Nagata, Kenji, Nakamura, Kiyonao, Nishioka, Kentaro, Ishiyama, Hiromichi, Ueno, Shuichi, Kokubo, Masaki, Yamazaki, Hideya, Watanabe, Kenta, Toyoda, Tatsuya, Akimoto, Tetsuo
• Format: Article
• Language: English
• Subjects: Androgen Antagonists - therapeutic use; Carcinoma, Ductal - drug therapy; Carcinoma, Ductal - radiotherapy; Disease-Free Survival; East Asian People; Humans; Male; Neoplasm Recurrence, Local - drug therapy; Prostate - pathology; Prostate-Specific Antigen; Prostatic Neoplasms - pathology; Radiation Oncology
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyac180

The clinical characteristics of prostate ductal carcinoma is still unclear, and treatment strategy has not yet been established due to its rarity. Therefore, we conducted a multicenter survey of radiation therapy for prostate ductal carcinoma in Japan. Data of patients with ductal carcinoma of the prostate treated with radiation therapy between 1996 and 2018 were extracted from the database of each facility. Fifty-two treatment records of 41 patients were collected from nine institutions. The treatment purpose and situations were varied curative intent to palliation. Twenty-eight patients received curative treatments. The median follow-up period of these patients was 68 months. Androgen deprivation therapy was combined with radiation therapy in 26 cases (93%). X-ray and particle irradiation was used. Radiation dose range was 63-78 Gy; 5-year overall survival, progression-free survival and biochemical relapse-free survival were 87.0, 79.3 and 79.3%, respectively. One patient experienced Grade 3 radiation proctitis and one experienced Grade 3 radiation cystitis. There were no Grade 4 or worse adverse events. Most patient received similar treatment with adenocarcinoma of prostate, and the clinical results were compatible. For more reliable evidence, further studies are required.